The stock will trade on the PIVOT-006 topline data and CORE-008 Cohort CX results expected in the coming weeks, not on the quarterly financials. The BLA completion timeline extension to Q4 2026 removes near-term regulatory catalyst risk but provides clarity. Monitor the AUA presentation on May 16 for the first combination data with gemcitabine.
CGON drugs
CGON drug pipeline →Price Chart
Executive Summary
CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, wider than the prior year's $0.45 loss, and total revenue of $1.1M. The key positive was a BLA submission timeline update for cretostimogene in HR BCG-unresponsive NMIBC, now expected to complete in Q4 2026, and a strong cash position of $1.1B. However, the widening net loss and lack of consensus estimates for this quarter make the financial results directionally negative for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- BLA completion for cretostimogene in HR BCG-unresponsive NMIBC expected Q4 2026, following FDA alignment discussions
- PIVOT-006 Phase 3 topline data in intermediate-risk NMIBC anticipated H1 2026
- CORE-008 Cohort CX Phase 2 first results to be presented at AUA 2026 on May 16
- Cash, cash equivalents and marketable securities of $1.1B as of March 31, 2026, up from $742.2M at Dec 31, 2025
- Net loss of $60.2M ($0.71/share) for Q1 2026 vs $34.5M ($0.45/share) in Q1 2025
- R&D expenses increased to $43.7M from $27.5M; G&A expenses increased to $20.8M from $14.8M
- Raised $391.4M net proceeds from ATM facility in Q1 2026, selling 6,941,407 shares
- Total revenues of $1.1M for Q1 2026 vs $52K in Q1 2025, primarily from commercial and development revenue
Financial Impact
Net loss widened by 74.7% YoY to $60.2M; cash position strengthened by $334M sequentially to $1.1B
Risk Factors
- PIVOT-006 Phase 3 topline data may miss efficacy or safety endpoints
- BLA submission delay beyond Q4 2026 could push potential approval into 2027
- Widening net losses with no near-term revenue visibility; cash burn rate increased to ~$60M/quarter
- Dilution risk from continued ATM usage (6.9M shares sold in Q1 2026)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-213440 |
| Document: ck0001991792-20260508.htm | 0001193125-26-213440 |
| Document: 0001193125-26-213440-index-headers.html | 0001193125-26-213440 |
| Document: 0001193125-26-213440-index.html | 0001193125-26-213440 |
| Document: 0001193125-26-213440.txt | 0001193125-26-213440 |
| 8-K Data (Synthetic) | 0001193125-26-213440 |
Track record
25 reports on CGON
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers